BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee S, Park YH, Kim KH, Cho EY, Ahn YC, Kim K, Shim YM, Ahn JS, Park K, Im YH. Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma. Br J Cancer. 2010;103:845-851. [PMID: 20700125 DOI: 10.1038/sj.bjc.6605831] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Kaira K, Serizawa M, Koh Y, Miura S, Kaira R, Abe M, Nakagawa K, Ohde Y, Okumura T, Murakami H, Tsuya A, Nakamura Y, Naito T, Takahashi T, Kondo H, Nakajima T, Endo M, Yamamoto N. Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors. Lung Cancer 2011;74:419-25. [DOI: 10.1016/j.lungcan.2011.04.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
2 Matsui Y, Hiraki T, Gobara H, Fujiwara H, Iguchi T, Shirakawa Y, Fujiwara T, Toyooka S, Kanazawa S. Percutaneous radiofrequency ablation for pulmonary metastases from esophageal cancer: retrospective evaluation of 21 patients. J Vasc Interv Radiol 2014;25:1566-72. [PMID: 25156828 DOI: 10.1016/j.jvir.2014.06.030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
3 Li W, Yue H. Thymidine phosphorylase: A potential new target for treating cardiovascular disease. Trends Cardiovasc Med 2018;28:157-71. [PMID: 29108898 DOI: 10.1016/j.tcm.2017.10.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
4 Nie X, Bhat R, Al-Saleem ED, Vonderheid EC, Hou JS. Expression of thymidine phosphorylase in lymph nodes involved with mycosis fungoides and sézary syndrome. Adv Hematol 2011;2011:875135. [PMID: 22162690 DOI: 10.1155/2011/875135] [Reference Citation Analysis]
5 Badary DM, Elkabsh MM, Mady HH, Gabr A, Kroosh SS. Prognostic and Predictive Role of Excision Repair Cross-complementation Group 1 and Thymidylate Synthase in Colorectal Carcinoma Patients Received FOLFOX Chemotherapy: An Immunohistochemical Study. Appl Immunohistochem Mol Morphol 2020;28:741-7. [PMID: 32118594 DOI: 10.1097/PAI.0000000000000841] [Reference Citation Analysis]
6 Rumiato E, Boldrin E, Malacrida S, Battaglia G, Sileni VC, Ruol A, Amadori A, Saggioro D. Identification of host variants associated with overall survival of esophageal cancer patients receiving platinum-based therapy. Pharmacogenomics 2020;21:393-402. [PMID: 32285752 DOI: 10.2217/pgs-2019-0165] [Reference Citation Analysis]
7 Shi Y, Qin R, Wang ZK, Dai GH. Nanoparticle albumin-bound paclitaxel combined with cisplatin as the first-line treatment for metastatic esophageal squamous cell carcinoma. Onco Targets Ther 2013;6:585-91. [PMID: 23737672 DOI: 10.2147/OTT.S44406] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
8 Valsecchi ME, Holdbrook T, Leiby BE, Pequignot E, Littman SJ, Yeo CJ, Brody JR, Witkiewicz AK. Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma? BMC Cancer. 2012;12:104. [PMID: 22436573 DOI: 10.1186/1471-2407-12-104] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
9 Abdo J, Bertellotti CA, Cornell DL, Agrawal DK, Mittal SK. Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting-Practice and Outcomes. Front Oncol 2017;7:151. [PMID: 28770168 DOI: 10.3389/fonc.2017.00151] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
10 Wood MD, Zaki BI, Gordon SR, Sutton JE Jr, Lisovsky M, Gui J, Bubis JA, Dragnev KH, Rigas JR. Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy. J Thorac Oncol 2013;8:487-94. [PMID: 23370365 DOI: 10.1097/JTO.0b013e3182829bf3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
11 Yu J, Gao J, Lu Z, Li Y, Shen L. Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine. Med Oncol. 2012;29:3029-3034. [PMID: 22766748 DOI: 10.1007/s12032-012-0292-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
12 Zhao HL, Han S, Li L, Ding JX, Yang JY. Role of ERCC1 in cisplatin resistance in esophageal cancer. Shijie Huaren Xiaohua Zazhi 2013; 21(16): 1493-1497 [DOI: 10.11569/wcjd.v21.i16.1493] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Huang J, Zhou Y, Zhang H, Qu T, Mao Y, Zhu H, Quan L, Xing P, Wang J, He J. A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy. Med Oncol. 2013;30:343. [PMID: 23263828 DOI: 10.1007/s12032-012-0343-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
14 Wang SS, Shen Y, Li HL, Wei X. Comparison of TYMS and ERCC1 genotypes between peripheral venous blood and tumor tissues of patients with gastric cancer. Shijie Huaren Xiaohua Zazhi 2013; 21(18): 1760-1765 [DOI: 10.11569/wcjd.v21.i18.1760] [Reference Citation Analysis]
15 Rao S, Beckman RA, Riazi S, Yabar CS, Boca SM, Marshall JL, Pishvaian MJ, Brody JR, Madhavan S. Quantification and expert evaluation of evidence for chemopredictive biomarkers to personalize cancer treatment. Oncotarget 2017;8:37923-34. [PMID: 27888622 DOI: 10.18632/oncotarget.13544] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
16 Cereda S, Milella M, Cordio S, Leone F, Aprile G, Galiano A, Mosconi S, Vasile E, Santini D, Belli C, Auriemma A, Novarino A, Vaccaro V, Martines C, Marino D, Lutrino SE, Palazzo V, Reinach B, Aldrighetti L, Reni M. Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma. Cancer Chemother Pharmacol 2016;77:109-14. [PMID: 26659366 DOI: 10.1007/s00280-015-2919-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
17 Kaira K, Ohde Y, Nakagawa K, Okumura T, Murakami H, Takahashi T, Kondo H, Nakajima T, Endo M, Yamamoto N. Thymidylate synthase expression is closely associated with outcome in patients with pulmonary adenocarcinoma. Med Oncol 2012;29:1663-72. [DOI: 10.1007/s12032-011-0069-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
18 Ko JC, Huang YC, Chen HJ, Tseng SC, Chiu HC, Wo TY, Huang YJ, Weng SH, Chiou RY, Lin YW. Metformin induces cytotoxicity by down-regulating thymidine phosphorylase and excision repair cross-complementation 1 expression in non-small cell lung cancer cells. Basic Clin Pharmacol Toxicol 2013;113:56-65. [PMID: 23362830 DOI: 10.1111/bcpt.12052] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]